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Background: Brain-derived neurotrophic factor (BDNF) is a potent neurotrophic factor that is implicated in the
regulation of food intake and body weight. Polyunsaturated fatty acids (PUFAs) localised in cell membranes have
been shown to alter the levels of BDNF in the brain, suggesting that PUFAs and BDNF could have physical
interaction with each other. To decipher the molecular mechanism through which PUFAs modulates BDNF’s
activity, molecular docking was performed for BDNF with PUFAs and its metabolites, with 4-Methyl Catechol
as a control.
Results: Inferring from molecular docking studies, lipoxin A4 (LXA4), and a known anti-inflammatory bioactive
metabolite derived from PUFAs, with a binding energy of −3.98 Kcal/mol and dissociation constant of 1.2mM
showed highest binding affinity for BDNF in comparison to other PUFAs and metabolites considered in the study.
Further, the residues Lys 18, Thr 20, Ala 21, Val 22, Phe 46, Glu 48, Lys 50, Lys 58, Thr 75, Gln 77, Arg 97 and
Ile 98 form hot point motif, which on interaction enhances BDNF’s function.
Conclusion: These results suggest that PUFAs and their metabolites especially, LXA4, modulate insulin resistance by
establishing a physical interaction with BDNF. Similar interaction(s) was noted between BDNF and resolvins and
protectins but were of lesser intensity compared to LXA4.
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Neurotrophins protect and promote the growth and de-
velopment of nerves [1]. They have potent effects on
neuronal differentiation, survival, neurite outgrowth,
synaptic formation, and plasticity [2,3]. Of all, BDNF
and its receptor TrkB are the most abundantly expressed
in hippocampus and cerebral cortex region of the brain
[4]. BDNF plays a crucial role in controlling body weight
and energy homeostasis [5]. Increased levels of BDNF
reduce food consumption and maintain energy balance* Correspondence: Undurti@hotmail.com; drak@snmail.org
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reproduction in any medium, provided the or[6]. Both central and peripheral administration of BDNF
decreased food intake, increased energy expenditure and
ameliorated hyperinsulinaemia and hyperglycaemia in
diabetic db/db mice [7-10].
TrkB activation by BDNF is essential for appetite regu-
lation and energy homeostasis [8]. BDNF mediated TrkB
signalling is an important downstream target for MC4R-
mediated signalling which participates in the regulation
of energy balance and feeding behaviour [6]. Mutations
in the TrkB receptor resulted in hyperphagia and morbid
obesity in humans and rodents. Conversely, peripheral or
central stimulation of TrkB by its natural ligands BDNF
or NT4 reduced body weight and food intake in mice,
supporting the idea that TrkB is a key anorexigenic signalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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system [11].
Polyunsaturated fatty acids such as linoleic acid (LA),
arachidonic acid (AA), α-linolenic acid (ALA), eicosa-
pentaneoic acid (EPA) and docosahexaenoic acid are
present in almost all cell membranes and regulate their
(cell membrane) fluidity, receptor number and affinity of
receptor to their respective hormones, peptides and
growth factors [12-15]. In this context, it is interesting
to note that dietary supplementation with omega-3
PUFAs reportedly normalizes BDNF levels which are
reduced following brain injury [16]. Omega-3 enriched
dietary supplement provides protection against reduced
plasticity and impaired learning ability associated with
brain injury in rats. High-fat diets, particularly those rich
in saturated fats, adversely affect insulin action and alter
homeostasis model assessment (HOMA) [17], which can
be prevented by n-3 PUFAs rich in eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA) by redu-
cing insulin resistance [18].
Furthermore, PUFAs are needed for synapse forma-
tion, neurite outgrowth and also have neuroprotective
actions [19,20]. Nerve growth cones are highly enriched
with AA-releasing phospholipases, which have been
implicated in neurite outgrowth. Cell membrane expan-
sion occurs through the fusion of transport organelles
with plasma membrane, and syntaxin 3, a plasma mem-
brane protein that is important in the growth of neur-
ites, is a direct target for AA, DHA and other PUFAs.
These (AA, DHA, and other PUFAs) polyunsaturated
fatty acids but not saturated and monounsaturated fatty
acids activate syntaxin 3.
SNAP25 (synaptosomal-associated protein of 25 kDa),
a syntaxin partner implicated in neurite outgrowth,
interacts with syntaxin 3 only in the presence of AA that
allowed the formation of the binary syntaxin 3-SNAP 25
complex. AA stimulated syntaxin 3 to form the ternary
SNARE complex (soluble N-ethylmaleimide-sensitive
factor attachment protein receptor), which is needed for
the fusion of plasmalemmal precursor vesicles into the
cell surface membrane that leads to membrane fusion
[21]. Thus, AA and DHA change the α-helical syntaxin
structure to expose SNARE motif for immediate SNAP
25 engagement that facilitates neurite outgrowth. This
could be one important mechanism by which AA, EPA
and DHA are able to enhance neurogenesis and bring
about their beneficial actions. In this context, it is inter-
esting to note that BDNF and TrkB are expressed in the
retinal ganglion cell layer and are able to influences the
morphological differentiation of the cells and act as cell
survival factors [22,23].
Since both BDNF and n-3 PUFAs levels are known to
be altered in diabetes and several other neurological
conditions, our current study aims to investigate theeffect of PUFAs and their metabolites on BDNF binding
towards the receptor, tropomyosin-related kinase-B
(TrkB) and its function through molecular docking
simulation. This will provide an insight on the bioactive
conformation of the protein through simulation studies
and the possible high affinity binding orientations of the
ligands, thus paving way for understanding the modulat-
ing mechanism of PUFAs and its metabolites on BDNF’s
affinity.
Methods
Molecular Dynamics simulation and Optimization
BDNF is a 247 amino acid protein, secreted in the extra-
cellular space. The 3D (three dimensional) structure of
the heterodimeric form of BDNF with Neurotrophin 3
[PDBID: 1BND] has been elucidated using X-ray crys-
tallography at 2.30Å resolution [24]. To optimize and
understand the conformational changes of the mono-
meric form of BDNF in the presence of explicit solvent,
molecular dynamics simulation was performed using
GROMACS (Groningen Machine for Chemical Simula-
tions) 4.3.1 package [25]. The model system was solvated
with three-point transferable intermolecular potential
(TIP3P) molecules [26] in a cubic water box with the
periodic boundary conditions set. To neutralize the sys-
tem, eight CL− ions were added and subjected to energy
minimization through Optimized Potentials for Liquid
Simulations (OPLS) force field using the steepest des-
cent integrator. After reaching the convergence limit,
the BDNF in the system was subjected to position-
restrains by keeping number of particles (N), pressure
(P) and temperature (T) constant (NPT). Using Particle
Mesh Ewald (PME) electrostatics method under NPT
conditions, final MD simulation of 5,000,000 was per-
formed for 10,000 ps (10 ns). Finally, the optimized
structure was utilized for further docking studies.
Small molecule optimization
3D Structural co-ordinates of 4-MC [CID 9958], LXA4
[CID 5280914], AA [CID 444899], EPA [CID 446284],
DHA [CID 445580], RVE1 [CID 10473088] and NPD1
[CID 16042541] were retrieved from Pubchem database
[27] and were geometry optimized using PRODRG ser-
ver with full charges [28].
Protein-Ligand docking
Molecular Docking simulation of the ligands with the
monomeric form of BDNF was carried out using Auto-
Dock 4.2 in combination with Lamarckian genetic al-
gorithm (LGA) to find the optimal conformation of the
ligand. The optimized 3D structure of BDNF was pre-
pared by removing water molecules and CL- ions; polar
hydrogens were added. Further, Kollman united atom
charges and Gasteiger charges were added to the receptor
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were assigned using the ADDSOL utility of Auto Dock
4.2. Flexibility of the ligands was assigned based on its
torsional degrees of freedom through Autotors option,
with the protein torsional angles were kept fixed through-
out the process of docking simulation [29-31].
Grid box covering the complete surface of BDNF was
constructed and used for molecular docking with a grid
spacing of 0.514 Å and the number of points in each grid
dimension set to 126 × 126 × 126. Further, Grid maps
were generated for each atom within the ligands using
Autogrid. Using LGA, molecular docking was carried out
with default parameters, except for the number of GA
runs which was set to 100, Maximum number of genera-
tions was set to 500 and maximum number of evalua-
tions set to 250 000 [32].
Further, cluster analysis was performed by sorting
the binding modes based on the binding energy within
the specified RMSD threshold, which was set to 2Å.
The optimal binding orientation of the ligand is the
one with the lowest binding energies picked up from
the cluster, which has maximum number of similar
conformations. However, agonistic mode was screened
based on the binding energy, dissociation constant and
through interaction studies [33]. Hot point interactions
mediating BDNF - ligand complex were analyzed and
visualized using PDBsum [34] and PyMOL (www.pymol.
org), respectively.
Results
Molecular Dynamics simulation of BDNF
MD simulation of the monomeric form of BDNF was
analyzed to gain a better insight into the stability and
dynamics nature of the molecule. Initial analysis wasFigure 1 Inferring the structural stability of BDNF through RMSD (a) aperformed to ascertain the quality of MD simulation
performed. The quality checks involves convergence of
thermodynamic parameters: temperature, potential and
kinetic energy. Analyzing the graphs, convergence in all
these parameters were observed, which is suggestive of
system’s equilibrium.
Further, Systems equilibrium in terms of structure was
inspected by comparing the Root Mean Square Devi-
ation (RMSD) of the C-alpha with respect to the starting
structure. Convergence of RMSD was inferred from the
graph towards the process of simulation (Figure 1a).
Root Mean Square Fluctuations (RMSF) was examined
to infer the flexibility in the residues during the course
of simulation (Figure 1b). These structural level analyses
were indicative of the system reaching equilibrium. And,
the final optimized monomeric form of BDNF was taken
for further docking analysis.Molecular Docking studies with a known reference
enhancer, 4-methyl catechol
Atsumi Nitta et al. proposed the stimulating effects of
4-MC on the synthesis of BDNF in neurons and astro-
cyte cells [35]. However, the agonistic binding mode of
4-MC on BDNF has not been studied. Therefore, mo-
lecular docking studies have been performed for BDNF
with 4-MC. Among 69 conformers in Cluster1, the one
with a lowest binding energies of −4.36Kcal/mol and dis-
sociation constant of 635.36 μM was considered for the
further analysis (Table 1). Inferring from interaction ana-
lysis, Tyr47, Glu48 and Asp99 showed hydrogen bond
interactions; wherein Val 13, Lys 18, Ala 21, Val 22, Phe
46, Arg 97 and Ile 98 showed non-bonded interactions
with 4-MC (Figure 2) (Table 1) and it could be a probablend RMSF (b).





Bonded and non-bonded interactions
4-MC -4.36 0.64 Val13, Lys18, Ala21, Val22, Phe46, Tyr47, Glu48, Arg97, Ile98 and Asp99
LXA4 -3.98 1.2 Thr 20, Ala 21, Phe 46, Lys 50, Cys 51, Lys 58,Cys 73, Arg 74, Thr 75, Gln 77,Arg 97, Ile 98
and Asp 99
EPA -3.67 2.06 Lys 18, Thr 20, Ala 21, Val 22, Phe 46, Glu 48, Lys 50,Arg 97, Ile 98 and Asp 99
AA -2.9 7.53 Lys 18, Thr 20, Ala 21, Val 22, Phe 46, Glu 48, Lys 50, Lys 58, Thr 75, Gln 77,Arg 97 and Ile 98
DHA -2.89 7.66 Lys 18(3.05), Thr 20, Ala 21, Val 22,Phe 46, Glu 48, Gln 77, Arg 97, Ile 98 and Asp 99
RVE1 -2.51 14.39 Lys 18, Thr 20, Ala 21,Val 22, Thr 28, Phe 46, Glu 48,Lys50, Gln 77, Arg 97, Ile 98 and Asp 99.
NPD1 -2.1 28 Lys 18, Thr 20, Ala 21, Val 22, Glu 48, Thr 75, Gln 77, Arg 97, Ile 98 and Asp 99.
Residues involved in Hydrogen bonding interactions are bolded.
Figure 2 Molecular interactions observed between BDNF and Ligands. Interactions observed between ligand (Blue) and BDNF (RED) with
hydrogen bonded interactions represented by YELLOW dashes.
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activity.
Molecular Docking studies with PUFAs
The binding conformation of PUFAs such as DHA, EPA
and AA has been inferred through molecular docking
studies. Among the PUFAs considered in the study, EPA,
an omega-3 fatty acid with a binding energy of −3.67
Kcal/mol and dissociation constant of 2.06mM showed
highest binding affinity for BDNF by forming a hydrogen
bond interaction with Lys 18 and Lys 50; non – bonded
interactions with Thr 20, Ala 21, Val 22, Phe 46, Glu 48,
Arg 97, Ile 98 and Asp 99. However, DHA and AA also
showed relatively higher binding affinity than the meta-
bolites with a binding energy of −2.9 Kcal/mol and −2.89
Kcal/mol, respectively (Table 1) (Figure 2).
Docking interaction analysis of BDNF with metabolites
REV1, NPD1 and LXA4
Molecular docking studies were performed to infer the
mechanism through which metabolites of PUFAs med-
iates BDNFs activity. LXA4, an endogenously synthesized
nonclassic eicosanoid, showed highest binding affinity for
BDNF in comparison to the PUFAs and metabolites con-
sidered in the study with a binding energy of −3.98 Kcal/
mol and dissociation constant of 1.2 mM. And, LXA4
established a network of hydrogen bond interactions with
Cys 51 and Lys 58; hydrophobic interaction with Thr 20,
Ala 21, Phe 46, Lys 50, Cys 73, Arg 74, Thr 75, Gln 77,
Arg 97, Ile 98 and Asp 99 of BDNF. Wherein, NPD1 and
REV1 showed comparatively lower binding affinity for
BDNF with the binding energy of −2.51 Kcal/mol and
−2.1 Kcal/mol, respectively (Table 1) (Figure 2).Figure 3 Hot Point residues (represented as sticks in magenta) of BDInspecting at the interacting residues, consensus in the
residues mediating interaction with PUFAs and its meta-
bolites was observed. Further, same residues were found
to establish interaction with 4-MC and, these residues
involve Lys 18, Thr 20, Ala 21, Val 22, Phe 46, Glu 48,
Lys 50, Lys 58, Thr 75, Gln 77, Arg 97 and Ile 98. Thus,
suggestive of these residues forming a probable hot point
motif mediating the BDNFs activity (Figure 3).Discussion
Molecular docking studies with the optimized model of
BDNF elicited the potential binding modes of agonists.
The active binding mode of the catechol compound, 4-
MC has been inferred through molecular docking stud-
ies. Thus confirming the 4-MC’s enhancing effect on
BDNF mRNA expression and secretion. However, the
inability of 4-MC to cross the Blood Brain Barrier limits
it therapeutic efficacy, which in turn requires novel
agonist for BDNF neurotrophic activity.
In case of endogenous agonists considered in the
study, LXA4 showed highest binding affinity for BDNF
by forming network of bonded and non- bonded interac-
tions with Thr 20, Ala 21, Phe 46, Lys 50, Cys 51, Lys
58, Cys 73, Arg 74, Thr 75, Gln 77, Arg 97, Ile 98 and
Asp 99 with a significant binding energy and disassoci-
ation constant.
EPA showed highest binding affinity with a binding
energy of −3.67Kcal/mol and disassociation of 2.06mM
among other PUFAs studied. Molecular interaction ana-
lysis showed polar and non-polar contacts with the bind-
ing cavity, which is shared by LXA4 involving the
residues: Lys 18, Thr 20, Ala 21, Val 22, Phe 46, Glu 48,NF (blue).
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showed lowest binding affinity for BDNF in comparison
to other metabolites considered in the study.
Further, the present study reveals the common binding
mode of PUFAs, metabolites and 4-MC to BDNF, in-
ferred through molecular docking studies (Figure 3).
Hence, the region of BDNF harbouring this common
binding mode may be the probable site where small mo-
lecular enhancers bind, and thereby promoting neuro-
trophic activity.
Moreover, this site also does not interfere with the
TrkB binding pockets in BDNF, which spans at the n-
terminal region [36]. Hence, it could be hypothesized
that the binding of PUFAs to BDNF shall exert allosteric
effect on the TrkB binding pocket, thereby modulating
the activity cascade. However, in vitro studies need to be
performed to ascertain the in silico predictions.
The results of the present study are consistent with
the hypothesis that PUFAs and their metabolites such as
lipoxins, resolvins and protectins interact with BDNF
and possibly, other neurotrophic factors and thus bring
about their beneficial actions both in diabetes mellitus
and neurological conditions such as depression [37-39].
Alternatively, the beneficial actions of BDNF in these
clinical conditions could also be attributed to its inter-
action with PUFAs. Thus, a better understanding of the
close interaction(s) between BDNF and PUFAs and their
metabolites may pave way for the development of newer
therapeutic strategies in diabetes mellitus, depression
and other clinical conditions in which they are believed
to play a significant role.
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